Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLARIVATE PLCCLVT · Entity 4778 | Director | May 13, 2026 | May 15, 2026 |
| Centessa Pharmaceuticals plcCNTA · Entity 35581 | Director · Chief Executive Officer | July 21, 2025 | July 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLARIVATE PLC
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 170,601 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Tax withholding · Disposed 8,178 · Balance 108,337 F1: Represents shares withheld for taxes. Row 2 · 2026-05-14 · Grant · Acquired 62,264 · Balance 170,601 F2: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc Amended and Restated 2019 Incentive Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for taxes.
F2: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc Amended and Restated 2019 Incentive Award Plan.
Centessa Pharmaceuticals plc
Report date July 21, 2025 · Filed July 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 221,017 |
Last balance in matching sequence
After 2025-07-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-07-21 · Exercise / conversion · Acquired 55,000 · Balance 276,017 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Row 2 · 2025-07-21 · Sale · Disposed 55,000 · Balance 221,017 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2033-02-01 | Direct | 150,000 |
Reported balance
After 2025-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-21 · Exercise / conversion · Disposed 55,000 · Balance 150,000 F5: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy trust | 38,000 |
Reported balance
Holding disclosure · report date 2025-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 38,000 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4: These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
F5: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2024 Filed Aug 23, 2024 21:13 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 46,651 | $12.30 | $573,905.27 |
DisclosureSEC source: 0001847903-24-000137 · wk-form4_1724447584.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 776,924 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 22, 2024 Filed Aug 22, 2024 21:15 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 506 | $12.23 | $6,188.38 |
DisclosureSEC source: 0001847903-24-000131 · wk-form4_1724361323.xml · nonDerivative · entry 3 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 823,575 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 21:15 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 3,674 | $12.25 | $44,989.23 |
DisclosureSEC source: 0001847903-24-000131 · wk-form4_1724361323.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 824,081 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:15 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 4,169 | $12.32 | $51,368.33 |
DisclosureSEC source: 0001847903-24-000131 · wk-form4_1724361323.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 827,755 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:32 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $9.03 | $327,454.89 |
DisclosureSEC source: 0001847903-24-000116 · wk-form4_1719952312.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,924 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| May 07, 2024 Filed May 8, 2024 20:34 UTC | CLARIVATE PLC CLVT · Entity 4778 | GrantOrdinary Shares | 23,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001764046-24-000074 · wk-form4_1715200474.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,387 F2 · shares: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc 2019 Incentive Award Plan. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:34 UTC | CLARIVATE PLC CLVT · Entity 4778 | Tax withholdingOrdinary Shares | 4,412 | $7.05 | $31,104.60 |
DisclosureSEC source: 0001764046-24-000074 · wk-form4_1715200474.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,646 F1 · shares: Represents shares withheld for taxes. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:17 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $11.30 | $409,771.90 |
DisclosureSEC source: 0001847903-24-000062 · wk-form4_1712089043.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868,187 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:07 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 576,800 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001847903-24-000033 · wk-form4_1706911620.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,800 Underlying: Ordinary Shares · 576,800 shares Expires 2034-02-01 F5 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:07 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 26,323 | $8.19 | $215,585.37 |
DisclosureSEC source: 0001847903-24-000033 · wk-form4_1706911620.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,450 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:07 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantOrdinary Shares | 144,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001847903-24-000033 · wk-form4_1706911620.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,773 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2025. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 00:43 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $7.96 | $288,653.48 |
DisclosureSEC source: 0001847903-24-000013 · wk-form4_1704242572.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 786,573 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 20:53 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $6.47 | $234,621.61 |
DisclosureSEC source: 0001847903-23-000173 · wk-form4_1696366367.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,836 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:32 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $5.90 | $213,955.33 |
DisclosureSEC source: 0001847903-23-000143 · wf-form4_168841995588866.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 859,099 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| May 04, 2023 Filed May 8, 2023 21:10 UTC | CLARIVATE PLC CLVT · Entity 4778 | GrantOrdinary Shares | 22,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001764046-23-000052 · wf-form4_168358023091755.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,058 F1 · shares: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc 2019 Incentive Award Plan. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:03 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 22,013 | $3.90 | $85,850.70 |
DisclosureSEC source: 0001847903-23-000084 · wf-form4_168064221788697.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 895,362 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:10 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 315,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001847903-23-000047 · wf-form4_167546223542666.xml · derivative · entry 3 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Ordinary Shares · 315,000 shares Expires 2033-02-01 F4 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:10 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantOrdinary Shares | 211,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001847903-23-000047 · wf-form4_167546223542666.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917,375 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024. Read SEC document |
| December 31, 2022 Filed Jan 5, 2023 00:25 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 44,025 | $3.10 | $136,477.50 |
DisclosureSEC source: 0001847903-23-000013 · wf-form4_167287828844971.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,975 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:16 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantOrdinary Shares | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025478 · doc4.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 01:28 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | PurchaseOrdinary Shares | 10,000 | $4.63 | $46,284.00 |
DisclosureSEC source: 0000899243-22-024303 · doc4.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 38,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.6000 to $4.6495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: These shares are held directly in a trust, for which the reporting person and his spouse serve as trustees. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 13:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | PurchaseOrdinary Shares | 5,000 | $9.74 | $48,700.00 |
DisclosureSEC source: 0000899243-22-004782 · doc4.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 28,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.65 to $9.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: These shares are held directly in a trust, for which the reporting person and his spouse serve as trustees. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 23:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $9.53 | $0.00 |
DisclosureSEC source: 0000899243-22-004681 · doc4.xml · derivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Ordinary Shares · 750,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 16, 2021 Filed Nov 19, 2021 00:00 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | PurchaseOrdinary Shares | 23,000 | $12.28 | $282,472.20 |
DisclosureSEC source: 0000899243-21-045311 · doc4.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 23,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $12.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: These shares are held directly in a trust, for which the reporting person and his spouse serve as trustees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.